Spyre Therapeutics Inc宣布，其候选药物Spy072与Il17-a/F联合疗法用于治疗化脓性汗腺炎（HS）的计划，预计将在2027年末或2028年初推进。这一时间表标志着该公司在炎症性疾病领域管线布局的重要节点，也反映出其对该联合方案临床开发节奏的审慎把控。
Spyre Therapeutics Inc宣布，其候选药物Spy072与Il17-a/F联合疗法用于治疗化脓性汗腺炎（HS）的计划，预计将在2027年末或2028年初推进。这一时间表标志着该公司在炎症性疾病领域管线布局的重要节点，也反映出其对该联合方案临床开发节奏的审慎把控。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.